Fusion Antibodies plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FAB.L research report →
Companywww.fusionantibodies.com
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies.
- CEO
- Adrian Robert Kinkaid
- IPO
- 2017
- Employees
- 27
- HQ
- Belfast, GB
Price Chart
Valuation
- Market Cap
- $15.88M
- P/E
- -9.80
- P/S
- 9.95
- P/B
- 19.81
- EV/EBITDA
- -11.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 18.17%
- Op Margin
- -118.73%
- Net Margin
- -91.92%
- ROE
- -210.32%
- ROIC
- -164.85%
Growth & Income
- Revenue
- $1.97M · 72.98%
- Net Income
- $-1,713,000 · 23.05%
- EPS
- $-0.02 · 55.36%
- Op Income
- $-1,779,000
- FCF YoY
- 22.42%
Performance & Tape
- 52W High
- $21.00
- 52W Low
- $5.86
- 50D MA
- $13.36
- 200D MA
- $14.23
- Beta
- 1.20
- Avg Volume
- 439.12K
Get TickerSpark's AI analysis on FAB.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FAB.L Coverage
We haven't published any research on FAB.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FAB.L Report →